532 related articles for article (PubMed ID: 22321739)
21. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
Baxter MA
Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296
[TBL] [Abstract][Full Text] [Related]
22. [Short-acting insulin analogs].
Wolffenbuttel BH; Heine RJ
Ned Tijdschr Geneeskd; 1998 Feb; 142(8):397-400. PubMed ID: 9562773
[TBL] [Abstract][Full Text] [Related]
23. Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus.
Wilde MI; McTavish D
Drugs; 1997 Oct; 54(4):597-614. PubMed ID: 9339963
[TBL] [Abstract][Full Text] [Related]
24. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin.
Heinemann L; Heise T; Wahl LC; Trautmann ME; Ampudia J; Starke AA; Berger M
Diabet Med; 1996 Jul; 13(7):625-9. PubMed ID: 8840095
[TBL] [Abstract][Full Text] [Related]
25. [The new insulins].
Krzentowski G
Rev Med Brux; 2005 Sep; 26(4):S241-5. PubMed ID: 16240869
[TBL] [Abstract][Full Text] [Related]
26. Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness.
Radermecker RP; Scheen AJ
Diabetes Metab Res Rev; 2004; 20(3):178-88. PubMed ID: 15133748
[TBL] [Abstract][Full Text] [Related]
27. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.
Jovanovic L; Giammattei J; Acquistapace M; Bornstein K; Sommermann E; Pettitt DJ
Clin Ther; 2004 Sep; 26(9):1492-7. PubMed ID: 15531011
[TBL] [Abstract][Full Text] [Related]
28. U-100, pH-Neutral formulation of VIAject(®) : faster onset of action than insulin lispro in patients with type 1 diabetes.
Heinemann L; Nosek L; Flacke F; Albus K; Krasner A; Pichotta P; Heise T; Steiner S
Diabetes Obes Metab; 2012 Mar; 14(3):222-7. PubMed ID: 21981286
[TBL] [Abstract][Full Text] [Related]
29. Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus.
Reynolds NA; Wagstaff AJ
Drugs; 2004; 64(17):1957-74. PubMed ID: 15329046
[TBL] [Abstract][Full Text] [Related]
30. Insulin aspart: a review.
Owens D; Vora J
Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):793-804. PubMed ID: 17014395
[TBL] [Abstract][Full Text] [Related]
31. Insulin analogues in the management of diabetes.
Vázquez-Carrera M; Silvestre JS
Methods Find Exp Clin Pharmacol; 2004; 26(6):445-61. PubMed ID: 15349139
[TBL] [Abstract][Full Text] [Related]
32. The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications.
Owens DR; Bolli GB
Diabetes Obes Metab; 2020 May; 22(5):743-754. PubMed ID: 31930670
[TBL] [Abstract][Full Text] [Related]
33. [Insulin therapy].
Brunetti P
Minerva Endocrinol; 2001 Jun; 26(2):65-86. PubMed ID: 11479436
[TBL] [Abstract][Full Text] [Related]
34. Defining the role of insulin lispro in the management of postprandial hyperglycaemia in patients with type 2 diabetes mellitus.
Giugliano D; Ceriello A; Razzoli E; Esposito K
Clin Drug Investig; 2008; 28(4):199-210. PubMed ID: 18345710
[TBL] [Abstract][Full Text] [Related]
35. A review of human and analogue insulin trials.
Gough SC
Diabetes Res Clin Pract; 2007 Jul; 77(1):1-15. PubMed ID: 17112621
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and pharmacodynamics of insulin aspart in patients with type 2 diabetes: assessment using a meal tolerance test under clinical conditions.
Ando H; Kurita S; Shimizu A; Kato K; Ishikura K; Taji K; Uno M; Takeshita Y; Misu H; Fujimura A; Kaneko S; Takamura T
Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):528-34. PubMed ID: 22642657
[TBL] [Abstract][Full Text] [Related]
37. Insulin glulisine.
Robinson DM; Wellington K
Drugs; 2006; 66(6):861-9. PubMed ID: 16706558
[TBL] [Abstract][Full Text] [Related]
38. Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine.
Ulrich H; Snyder B; Garg SK
Vasc Health Risk Manag; 2007; 3(3):245-54. PubMed ID: 17703632
[TBL] [Abstract][Full Text] [Related]
39. Insulin analogues: new dimension of management of diabetes mellitus.
Siddiqui NI
Mymensingh Med J; 2007 Jan; 16(1):117-21. PubMed ID: 17344794
[TBL] [Abstract][Full Text] [Related]
40. New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations.
Roach P
Clin Pharmacokinet; 2008; 47(9):595-610. PubMed ID: 18698880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
